On this episode of Stock Movers:

- UnitedHealth Group (UNH) shares fell the most in 26 years. The company cut its annual forecast and reported its first earnings miss in more than a decade, in a foreboding sign that weighed on other insurance stocks. UnitedHealth Group said it was blindsided by rising medical costs as the first quarter closed, upending a forecast it had affirmed just three months ago. 

- Eli Lilly (LLY) shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of the fastest growing markets in medicine. The triumph of Ozempic, the blockbuster diabetes shot from Novo Nordisk A/S, and related drugs including Zepbound and Mounjaro from Lilly, has set off an all-out push to develop a pill that’s easier to take and less expensive to make. While rivals including Pfizer have suffered setbacks, analysts said success is critical to creating the $130 billion market they predict by the end of the decade.

- Fidelity National Information Services (FIS) shares surged while Global Payments (GPN) shares are down. This comes after the company agreed to buy rival Worldpay from GTCR and Fidelity National Information Services. Global Payments also agreed to offload its issuer-solutions business to FIS. Some analysts are skeptical of Global Payments’ ability to accelerate growth following the Worldpay acquisition, while KBW downgraded Global Payments, saying its outlook is now more complicated.

On this episode of Stock Movers: - UnitedHealth Group (UNH) shares fell the most in 26 years. The company cut its annual forecast and reported its first earnings miss in more than a decade, in a foreboding sign that weighed on other insurance stocks. UnitedHealth Group said it was blindsided by rising medical costs as the first quarter closed, upending a forecast it had affirmed just three months ago. - Eli Lilly (LLY) shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what&rsquo;s already one of the fastest growing markets in medicine. The triumph of Ozempic, the blockbuster diabetes shot from Novo Nordisk A/S, and related drugs including Zepbound and Mounjaro from Lilly, has set off an all-out push to develop a pill that&rsquo;s easier to take and less expensive to make. While rivals including Pfizer have suffered setbacks, analysts said success is critical to creating the $130 billion market they predict by the end of the decade. - Fidelity National Information Services (FIS) shares surged while Global Payments (GPN) shares are down. This comes after the company agreed to buy rival Worldpay from GTCR and Fidelity National Information Services. Global Payments also agreed to offload its issuer-solutions business to FIS. Some analysts are skeptical of Global Payments&rsquo; ability to accelerate growth following the Worldpay acquisition, while KBW downgraded Global Payments, saying its outlook is now more complicated.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

UnitedHealth Falls, Eli Lily Surges, FIS Strikes a Deal

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d7333462-9cc0-4346-a09a-b2c2013cabef/transcript